93 related articles for article (PubMed ID: 11904968)
1. [Monoclonal antibody therapy for disorders of hemostasis and coagulation].
Nishimura S; Ishida T; Imai K
Nihon Rinsho; 2002 Mar; 60(3):525-30. PubMed ID: 11904968
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders.
Franchini M; Veneri D; Lippi G; Stenner R
Thromb Haemost; 2006 Aug; 96(2):119-25. PubMed ID: 16894452
[TBL] [Abstract][Full Text] [Related]
3. Prevention of renal fibrin deposition in endotoxin-induced DIC through inhibition of PAI-1.
Montes R; Declerck PJ; Calvo A; Montes M; Hermida J; Muñoz MC; Rocha E
Thromb Haemost; 2000 Jul; 84(1):65-70. PubMed ID: 10928472
[TBL] [Abstract][Full Text] [Related]
4. Chronic refractory idiopathic thrombocytopenic purpura (ITP) and anti-CD20 monoclonal antibody: a case report.
Latifzadeh SZ; Entezari V
Clin Appl Thromb Hemost; 2006 Oct; 12(4):489-92. PubMed ID: 17000895
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in the treatment of autoimmune haematological disorders.
Garvey B
Br J Haematol; 2008 Apr; 141(2):149-69. PubMed ID: 18318765
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for the treatment of childhood chronic idiopathic thrombocytopenic purpura and hemophilia with inhibitors.
Franchini M; Zaffanello M; Veneri D; Lippi G
Pediatr Blood Cancer; 2007 Jul; 49(1):6-10. PubMed ID: 17311349
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders.
Dierickx D; Delannoy A; Saja K; Verhoef G; Provan D
Am J Hematol; 2011 Mar; 86(3):278-91. PubMed ID: 21328427
[TBL] [Abstract][Full Text] [Related]
8. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
9. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
[TBL] [Abstract][Full Text] [Related]
10. Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura.
Aggarwal A; Catlett JP
South Med J; 2002 Oct; 95(10):1209-12. PubMed ID: 12425512
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation.
Ohkura N; Soe G; Kohno I; Kumeda K; Wada H; Kamikubo Y; Shiku H; Kato H
Blood Coagul Fibrinolysis; 1999 Sep; 10(6):309-19. PubMed ID: 10493212
[TBL] [Abstract][Full Text] [Related]
12. [Targeting CD20 in rheumatoid arthritis].
Saito K; Tanaka Y
Nihon Rinsho; 2007 Jul; 65(7):1243-9. PubMed ID: 17642239
[TBL] [Abstract][Full Text] [Related]
13. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
[TBL] [Abstract][Full Text] [Related]
14. [Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody].
Tobinai K
Nihon Rinsho; 2002 Mar; 60(3):468-72. PubMed ID: 11904960
[TBL] [Abstract][Full Text] [Related]
15. [A novel molecular marker for thrombus formation and life prognosis--clinical usefulness of measurement of soluble fibrin monomer-fibrinogen complex (SF)].
Koga S
Rinsho Byori; 2004 Apr; 52(4):355-61. PubMed ID: 15164605
[TBL] [Abstract][Full Text] [Related]
16. [CD 40 L blockade as a novel treatment for chronic ITP refractory to corticosteroids and splenectomy].
Kuwana M
Rinsho Ketsueki; 2003 Feb; 44(2):82-9. PubMed ID: 12692980
[No Abstract] [Full Text] [Related]
17. Disseminated intravascular coagulation: What's new?
Levi M
Crit Care Clin; 2005 Jul; 21(3):449-67. PubMed ID: 15992667
[TBL] [Abstract][Full Text] [Related]
18. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
Nishida M; Usuda S; Okabe M; Miyakoda H; Komatsu M; Hanaoka H; Teshigawara K; Niwa O
Int J Oncol; 2007 Jul; 31(1):29-40. PubMed ID: 17549402
[TBL] [Abstract][Full Text] [Related]
19. Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome.
Roser-Jones C; Chan M; Howard EL; Becker KC; Rusconi CP; Becker RC
Cardiovasc Ther; 2011 Aug; 29(4):e22-35. PubMed ID: 21749674
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD20 monoclonal antibody therapy in multiple myeloma.
Kapoor P; Greipp PT; Morice WG; Rajkumar SV; Witzig TE; Greipp PR
Br J Haematol; 2008 Apr; 141(2):135-48. PubMed ID: 18318769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
